BioSpace News Archive

Business

Ligand Reports Second Quarter 2022 Financial Results

Raises 2022 Financial Guidance Conference Call Begins at 4:30 p.m. Eastern Time Ligand Pharmaceuticals Incorporated today reported financial results for the three and six months ended June 30, 2022 and provided an operating forecast and program updates.

August 8, 2022
·
29 min read
Business

Quanterix Corporation Releases Operating Results for Second Quarter 2022, Announces Business Re-Alignment Plan and Revises 2022 Guidance

Quanterix Corporation, a company expanding the limits of exploration with ultrasensitive biomarker detection, announced operating results for the three months ended June 30, 2022.

August 8, 2022
·
10 min read
Genetown

Quanterix Announces the Resignation of Kevin Hrusovsky as Executive Chairman of Board of Directors

Quanterix Corporation, a company expanding the limits of exploration with ultrasensitive biomarker detection, announced that E. Kevin Hrusovsky is stepping down as Executive Chairman of its Board of Directors.

August 8, 2022
·
3 min read
Business

DermTech Reports Second-Quarter 2022 Financial Results; Company Updates Full-Year 2022 Outlook

DermTech, Inc., a leader in precision dermatology enabled by a non-invasive skin genomics platform, reported its second-quarter 2022 financial results and updated its full-year 2022 outlook.

August 8, 2022
·
9 min read
Pharm Country

Scientific Industries’ Scientific Bioprocessing (SBI) Introduces DOTS, The New Sensor Platform to Digitally Simplify Bioprocessing

Scientific Industries announced its subsidiary Scientific Bioprocessing announces the launch of DOTS, a visionary sensor platform for bioprocessing at the 2022 Annual Meeting of the Society for Industrial Microbiology and Biotechnology in San Francisco from August 7-10 at the Hyatt Regency.

August 8, 2022
·
4 min read
BioMidwest

Aytu BioPharma Announces Launch of Public Offering - Aug 08, 2022

Aytu BioPharma, Inc. announced the launch of an underwritten public offering of shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock, and accompanying warrants to purchase its common stock.

August 8, 2022
·
5 min read
Business

Acumen Pharmaceuticals to Report Second Quarter 2022 Financial Results on August 15, 2022

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical stage biopharmaceutical company focused on the development of novel targeted therapeutics for Alzheimer’s disease (AD), today announced that the Company will report its financial results for the second quarter 2022 on Monday, August 15, 2022.

August 8, 2022
·
1 min read
Medicenna Announces the Launch of a Marketed Underwritten Public Offering of Units - Aug 08, 2022

Medicenna Therapeutics Corp., a clinical stage immunotherapy company, announced the launch of a marketed underwritten public offering of units of the Company in the United States.

August 8, 2022
·
5 min read
Business

IGM Biosciences Announces Second Quarter 2022 Financial Results and Provides Corporate Update

IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced its financial results for the second quarter ended June 30, 2022 and provided an update on recent developments.

August 8, 2022
·
10 min read
Business

Vicarious Surgical Reports Second Quarter 2022 Financial Results

Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve patient outcomes as well as both the cost and efficiency of surgical procedures, today announced financial results for the quarter ended June 30, 2022.

August 8, 2022
·
10 min read